DIRS.INFO The most relevant business & tech news

☆ Novartis raises 2023 forecast, maps out Sandoz spin-off
▼ + stars: | 2023-07-18 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Companies Novartis AG FollowSandoz GmbH FollowFRANKFURT, July 18 (Reuters) - Novartis (NOVN.S) on Tuesday raised its full-year earnings forecast on strong drug sales and mapped out the planned spin-off and stock market debut of its generic medicines division Sandoz for early October. The Swiss drugmaker said in a statement it expected group core operating income to grow by a "low double-digit" percentage in 2023, up from high single-digit growth previously projected. Novartis shareholders will vote on the proposed Sandoz spin-off and complete separation at an extraordinary general meeting on Sept. 15. Gains were driven by better-than-expected sales of heart failure drug Entresto, up 37% in local currencies at $1.52 billion. Kesimpta, a new once-a-month injection against multiple sclerosis, also beat expectations with quarterly revenues more than doubling to $489 million.

Persons: Swiss drugmaker, Sandoz, Harry Kirsch ., Kirsch, Ludwig Burger, Rachel More, Sharon Singleton Organizations: Novartis, Sandoz, FRANKFURT, SIX Swiss Exchange, Swiss pharma, Thomson Locations: Swiss, United States, New Jersey

☆ It’s official: Silicon Valley’s entire business model is a scam
▼ + stars: | 2023-07-18 | by ( Adam Rogers | ) www.businessinsider.com time to read: +13 min

The problem is, conservative economists at the University of Chicago have spent the past 50 years insisting that under capitalism, predatory pricing is not a thing. Predatory companies could never recoup their losses, which meant predatory behaviors are irrational. Lots of economists have come up with solid counter-counterarguments to the Chicago School's skepticism about predatory pricing. A company that engages in predatory pricing and its late-stage investors might not recoup, but the venture investors do. "If people in Silicon Valley start thinking about this as a predatory pricing scam, then I think the late-stage investors will start asking questions."

Persons: Matt Wansley, Wansley, we're, Uber, Cardozo, Sam Weinstein, gobs, you've, —, Brooke, Spencer Waller, Matsushita, Weinstein —, Justice Department —, it's, Weinstein, Matt, that's, Will Uber, Waller, David, Maurer, they've, Adam Rogers Organizations: Lyft, Big Tech, Cardozo School of Law, Justice Department, University of Chicago, Chicago School, Supreme, Matsushita Electric Industry Co, Zenith Radio Corp, Brooke Group, Brown & Williamson Tobacco Corp, United, Loyola's School of Law, Venture, Matsushita, VCs, Chicago, Loyola, pharma, aha, Wansley Locations: United States, Chicago, Silicon Valley, Silicon

REUTERS/Remo CasilliLONDON, July 18 (Reuters) - The world is baking under extreme heat - with Asia, Europe and the United States all dealing with scorching temperatures. LESS OBVIOUS RISKSAir pollution also poses a health risk, with serious potential effects from wildfire smoke including inflammation and tissue damage. Dr Vikki Thompson, Climate Scientist, Royal Netherlands Meteorological Institute, said extreme heat often contributes to poorer mental health, as well as a rise in car crashes and drownings. Location matters, too; people are at higher risk in places where they are not used to such heat, including parts of Europe. It is also important to check on the vulnerable, including older and isolated people, they said.

Persons: Remo Casilli, Liz Stephens, Dr Vikki Thompson, Modi Mwatsama, Heatstroke, Jennifer Rigby, Kate Turton, Catherine Evans Organizations: REUTERS, Remo Casilli LONDON, WHO, heatwaves, Britain's University of Reading, Royal Netherlands Meteorological Institute, Wellcome, Public, Thomson Locations: Italy, Rome, Asia, Europe, United States, London

☆ Read the 17-page pitch deck that helped a former WME agent raise $25 million in VC to capitalize on celebrity-backed brands like Gal Gadot's mac and cheese
▼ + stars: | 2023-07-18 | by ( Lucia Moses | ) www.businessinsider.com time to read: +5 min

Read the deck he's using to raise his first venture round of $50 million. In 2018, he left Roar, the management company he started in 2003, to launch Fourward, a management, production, and investment firm. And Fourward has just announced its first VC fund, Fourward Ventures, an early-stage growth fund focused on investments in health and wellness, sustainability, and consumer packaged goods. Fourward says it's looking to companies that disrupt traditional consumer categories, drive societal change, and have celebrity tie-ins. Check out the pitch deck Fourward used to raise the first $25 million of its planned $50 million fund.

Persons: Will Ward, He's, Adam Sandler, Ryan Reynolds, Chris Hemsworth, Zac Brown, Fourward, Gal Gadot, Jay, Austin Nelson, Ward, Chris Hemsworth's, Mark Bezos, there's, he's Organizations: CAA, Roar, Fourward Ventures, Marcy Venture Partners, Bryn Pharma, Corp, HighPost, Hollywood Locations: Fourward, Hollywood, Nashville, —, Centr

☆ Novartis buyback offers partial cure for M&A risk
▼ + stars: | 2023-07-18 | by ( ) www.reuters.com time to read: +2 min

LONDON, July 18 (Reuters Breakingviews) - Novartis’s (NOVN.S) bumper buyback will offer a little relief to investors. Many had been waiting to see what the $225 billion Swiss pharma giant would do with an extra $20 billion burning a hole in its pocket after Roche(ROG.S) bought back its stake in 2021. It needs new drugs to replenish its pipeline and boost an ailing share price, which has still not recovered since the pandemic. But on Tuesday, CEO Vasant Narasimhan said he will launch a $15 billion buyback programme. The Swiss drugmaker’s $15.4 billion of net debt is less than 1 times its forecast 2023 EBITDA, according to Refinitiv.

Persons: Roche, Vasant Narasimhan, can’t, Aimee Donnellan, Xavier Niel’s, Neil Unmack, Streisand Neto Organizations: Reuters, Swiss pharma, Alcon, Madrigal Pharmaceuticals, Novartis, Twitter, Xavier Niel’s GAM, Commonwealth Games, Thomson Locations: Swiss

☆ BridgeBio's heart disease drug meets late-stage study goal, shares soar
▼ + stars: | 2023-07-17 | by ( Khushi Mandowara | ) www.reuters.com time to read: +2 min

July 17 (Reuters) - BridgeBio Pharma Inc's (BBIO.O) experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares surging 65% on Monday. BridgeBio's drug improved survival by 81% in the study patients compared to 74% on the placebo, and also reduced frequency of heart disease-related hospitalization by 50%. The California-based company also provided additional data comparing it with Pfizer's drug. Acoramidis showed 92% improvement on heart failure test, compared to patients on placebo and Pfizer's drug at 30 months. The additional data suggests that BridgeBio's drug was better than tafamidis in controlling the disease, said TD Cowen analyst Tyler Van Buren.

Persons: acoramidis, Acoramidis, Cowen, Tyler Van, Luca Issi, BridgeBio, BridgeBio's, Khushi, Nivedita Bhattacharjee Organizations: BridgeBio Pharma, Alnylam Pharmaceuticals, Ionis Pharmaceutical, RBC Capital, U.S . Food, Drug Administration, Thomson Locations: U.S, California, Tyler Van Buren, Bengaluru

☆ Argenx drug boost is mixed blessing for suitors
▼ + stars: | 2023-07-17 | by ( ) www.reuters.com time to read: +2 min

LONDON, July 17 (Reuters Breakingviews) - Argenx (ARGX.BR) has long been a presumed takeover target for drugmakers like Pfizer (PFE.N). Many of its remedies like Vyvgart, which delivered positive drug trial results on Monday, are likely to reach their peak just as the big drugmakers’ revenues come under patent pressure. Still, the more successful Argenx becomes the more expensive it will be for a potential bidder. Since then the company’s shares have nearly doubled, including a 26% bump on Monday thanks to the positive trial results. Argenx’s drug trial success may give bidders comfort they are not buying a dud, but that reassurance comes with a downside.

Persons: Argenx, Prometheus, Aimee Donnellan, George Hay, Pranav Kiran Organizations: Reuters, Pfizer, Big Pharma, Twitter, Cathay, Thomson Locations: Belgian

☆ Stocks making the biggest moves midday: Ford, AT&T, Yelp, Figs and more
▼ + stars: | 2023-07-17 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Paramount Global — The entertainment company's stock shed 4.4% after the new "Mission: Impossible" movie underperformed expectations at the box office. The Wall Street firm said Progressive's valuation is now compelling after its poor results in June, and said the company has long-term earnings power and growth potential. Yeti — The cooler company's stock fell 5.8% following a downgrade to underweight from sector weight by KeyBanc. The Wall Street firm cited concerns over Yeti's growth and its heavy wholesale channel inventory. State Street — The asset manager slipped more than 3.1% after the firm was downgraded by multiple Wall Street firms, including JPMorgan.

Persons: Rivian, Tesla —, Knight, Yelp, Goldman Sachs, Raymond James, Cantor, —, Samantha Subin, Alex Harring, Tanaya Macheel, Brian Evans Organizations: Ford —, Ford, Tesla — Elon, Constellation Software, Intercontinental Exchange, Citi, BridgeBio Pharma —, Activision, Microsoft, Sony, PlayStation, Activision Blizzard, Paramount Global, Variety, Apellis Pharmaceuticals, American, JPMorgan, Wall, State Street's, Iris Energy

☆ Here's what investors should have top of mind ahead of a busy week of earnings
▼ + stars: | 2023-07-14 | by ( ) www.cnbc.com time to read: 1 min

Here's what investors should have top of mind ahead of a busy week of earningsShares of Eli Lilly are bouncing back Friday after what's been a tough week for our much-loved pharma company. Earnings season has officially kicked off and can take the market higher but there are still pockets of weakness given how overbought the market is.

Persons: Eli Lilly, what's Organizations: pharma

☆ 3 health-care stocks are in the headlines. How the news impacts our investments
▼ + stars: | 2023-07-13 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

In April, alongside its first-quarter results, J & J raised its full-year sales guidance by about $1 billion and its earnings-per-share outlook by 15 cents. Clearing this overhang would help reduce the discount at which J & J shares to pharmaceutical peers, the firm said. The Club's take: JPMorgan's thinking on J & J aligns quite closely with our own. The dark cloud of talc lawsuits continues to keep a lid on J & J's stock price. Joaquin Duato, chief executive officer of Johnson & Johnson, at the company's headquarters in New Brunswick, New Jersey, U.S., on Thursday, April 21, 2022.

Persons: Johnson, Eli Lilly, J, Wells, Wells Fargo, Eli Lilly's, —, Eisai, Biogen, Bloomberg, we've, Jim Cramer's, Jim Cramer, Jim, Joaquin Duato, Amir Hamia Organizations: Johnson, JPMorgan, pharma, U.S ., Humana, UnitedHealth, Bloomberg, U.S, Mayo Clinic, Club, GE Healthcare, CNBC, Getty, & $ Locations: U.S, California, Wells Fargo, Rochester , Minnesota, New Brunswick , New Jersey

☆ AI-Targeted Internet Advertisements Fueling Looming Addiction Crisis
▼ + stars: | 2023-07-13 | by ( Albert Fox Cahn | ) www.businessinsider.com time to read: +13 min

A new breed of direct-to-consumer services is aggressively using targeted ads to sell habit-forming medications. In short, AI and surveillance capitalism, which empower today's targeted ads, have joined forces with the deadly OxyContin playbook. As the Journal reported, after ADHD medications grew to 20% of the VC-funded company's business, driving a $4.8 billion valuation, things came crashing to earth. We as a society may have come to accept being stalked by targeted ads, but consequences are much graver when the product itself is a danger. But above all, we need rules that ban targeted ads for drugs that can get patients hooked.

Persons: Taylor Swift, they're, haven't, Van Zee, OxyContin, prescribers, Dr, David Sack, Anthony Yeung, recreationally, Yann Poncin, shih, Ryan Haight, Ryan Haight Act's, Albert Fox Cahn Organizations: Circle, Purdue, American, of Public Health, Sackler family's pharma, Physicians, Yale School of Medicine, Bloomberg, Drug Enforcement Agency, Department of Health, Human Services, Ryan, Twitter, FDA Locations: Canadian, California, United States, New Zealand, New York

Aspartame is one of the world's most popular sweeteners, used in products from Coca-Cola diet sodas to Mars' Extra chewing gum. In its first declaration on the additive, announced early on Friday, the Lyon-based International Agency for Research on Cancer (IARC) said aspartame was a "possible carcinogen". Several scientists not associated with the reviews said the evidence linking aspartame to cancer is weak. There was also some limited evidence that aspartame has some chemical properties that are linked to cancer, the IARC said. Scientists with no links to the WHO reviews said the evidence that aspartame caused cancer was weak.

Persons: Francesco Branca, " Branca, JECFA, Branca, Mary Schubauer, Paul Pharaoh, Pharaoh, Kate Loatman, Frances Hunt, Wood, Richa Naidu, Caroline Humer, Catherine Evans Organizations: World Health Organization, WHO, Agency for Research, Cancer, Food, Agriculture Organization, FAO, Reuters, Cedars Sinai Medical Center, International Council of Beverage Associations, International, Thomson Locations: Lyon, Geneva, United States, Europe, Cedars, Los Angeles

Reuters reported last month that the cancer research arm of the World Health Organization (WHO), known as the International Agency for Research on Cancer (IARC), was set to make that declaration on July 14, according to two sources with knowledge of the process. The designation as "possibly carcinogenic to humans" will provide an incentive to fund more rigorous research into the safety question, toxicology and cancer experts say. "We have been pushing for an IARC review for many years now." But no action was taken until 2022, after aspartame was again nominated for review by CSPI and Melnick in 2019. The research body has said "new evidence" prompted its aspartame review, without giving any details.

Persons: Andy Smith, Smith, Coke, Peter Lurie, Lurie, James Huff, Ron Melnick, CSPI, There's, Samuel Cohen, Erik Millstone, Millstone, Jennifer Rigby, Michele Gershberg, Catherine Evans Organizations: Reuters, World Health Organization, WHO, International Agency for Research, Cancer, MRC, Unit, University of Cambridge, Cola's, Regulators, for Science, Joint Food and Agriculture Organization, U.S . National Institutes of Health, University of Nebraska Medical Center, University of Paris, Britain's University of Sussex, Thomson Locations: United States, U.S, France

☆ FDA approves Opill, the first over-the-counter birth control pill
▼ + stars: | 2023-07-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

HRA Pharma expects a final decision by the FDA this summer on its application for nonprescription sales of Opill, which is generically called norgestrel. The Food and Drug Administration on Thursday approved the first over-the-counter birth control pill, a landmark decision that will allow more women and girls in the U.S. to prevent unintended pregnancies without a prescription. The daily pill, called Opill, was first approved by the FDA as a prescription in 1973. Medical organizations like the American College of Obstetricians and Gynecologists and women's health advocates have pushed for wider access. More than 50 members of Congress in March 2022 also called on FDA Commissioner Dr. Robert Califf to ensure the agency reviewed applications for over-the-counter birth control pills without delay.

Persons: Biden, Wade, –, Welgryn, Robert Califf, Patrizia Cavazzoni, Opill Organizations: HRA Pharma, FDA, Drug Administration, American College of Obstetricians, FDA's Center, Drug, Research Locations: U.S, Paris, Dublin

☆ UBS upgrades Big Pharma stock after shares drop on poor drug results
▼ + stars: | 2023-07-13 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

UBS upgraded AstraZeneca 's stock to a "buy" rating despite the drugmaker's trial of a lung cancer medication recently delivering poor results. The investment bank said the subsequent drop in the pharma giant's stock price now meant that "investors can come back to the stock for the performance of in-market products." London-listed shares of AstraZeneca dropped by 8% in a single day, the most in years, after releasing the results of the "TropionLung01" trial for drug candidate "Dato-DXd." UBS expects shares of AstraZeneca to rise by 27% to £13 ($16.8) a share over the next 12 months. These include Imfinzi, a drug for bile duct or gallbladder cancer, and Tagrisso, a treatment for non-small cell lung cancer in adults.

Persons: Michael Leuchten, UBS Michael Leuchten AZN Organizations: UBS, AstraZeneca, pharma, DXd, FDA, Johnson Locations: London, Swiss, Tagrisso

July 13 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the first over-the-counter contraceptive pill, paving the way for millions of women in the country to purchase birth control without prescription. Perrigo will next week share its pricing plan for the pill, which will be available in stores and online in the first quarter of next year. Women should take a progestin-only pill within the same three hours every day to avoid pregnancy. The National Catholic Bioethics Center and other groups have opposed making Opill available without prescription, saying physicians should be involved in health decisions, especially for teenagers, along with parental supervision, to avoid harm. Perrigo gained the daily-use pill first through its $2.13 billion acquisition of Paris-based HRA Pharma in 2021.

Persons: Roe, Wade, Xavier Becerra, Opill, Jeffrey Singer, Perrigo, Manas Mishra, Sriparna Roy, Arun Koyyur Organizations: U.S . Food, Drug Administration, Perrigo, Human Services, Cato Institute, FDA, Catholic Bioethics Center, HRA Pharma, Thomson Locations: U.S, Paris, Bengaluru

[1/3] A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. It highlights the challenge Novo and rivals face in convincing European governments to pay for obesity drugs, which analysts say is likely to slow their take-up there. Germany's health ministry told Reuters there were no plans to change the law to cover weight loss drugs. DIFFERENT PICTUREIn the United States, the federal Medicare health plan for older Americans is prohibited from covering weight-loss drugs. Many health plans paid for by large employers will cover Wegovy, although they may require that patients try a rigorous diet programme or cheaper drugs first.

Persons: Jim Vondruska, Wegovy, Martin Merkel, Merkel, Duane Mellor, Novo, Lars Fruergaard Jorgensen, Michael Wirtz, Terence McManus, Phil McEwan, they've, McEwan, Patricia Weiss, Josephine Mason, Catherine Evans Organizations: REUTERS, Novo Nordisk, Wegovy, Europe's, pharma, European Union, Endocrinology Society, Aston University in, Reuters, Bellevue Asset Management, Barclays, Thomson Locations: Chicago , Illinois, U.S, Germany, FRANKFURT, Aston University in Birmingham, England, Wegovy, Europe, Danish, Berlin, Norway, Denmark, Britain, United States, Switzerland, Bellevue, EU, Cardiff , Wales, Frankfurt

☆ Focus: Biotech firms target weight-loss drugs without Wegovy's side-effects
▼ + stars: | 2023-07-07 | by ( Maggie Fick | ) www.reuters.com time to read: +8 min

[1/7] Rebecca Vogt, a former user of the weight-loss drug Wegovy, poses for a photo, in Irving, New York, U.S., June 20, 2023. It leads to 22.5% weight loss, according to a Lilly trial published last year. An even earlier stage biotech firm, Antag Therapeutics in Denmark, told Reuters that the ballooning obesity market has improved its fundraising prospects. It curbs appetite by restoring the natural release of GLP-1 and other hormones, without causing nausea, Phase I data showed. The effect of the drug on weight loss is being tested in the Phase II study.

Persons: Rebecca Vogt, Handout, Wegovy, Vogt, Jayson Dallas, Noushin Irani, Mounjaro, Eli Lilly's, Lilly, Andrew Levin, Rivus, Mark Fineman, Ashish Nimgaonkar, Nimgaonkar, Alexander Sparre, Ulrich, Tim Opler, Opler, Stifel, Maggie Fick, Josephine Mason, Daniel Flynn Organizations: REUTERS, Nordisk's, Food and Drug Administration, U.S, Reuters, Rivus Pharmaceuticals, Investors, Deutsche, FDA, Pfizer, Capital Management, Rivus, Therapeutics, Johns Hopkins University, pharma, Antag Therapeutics, Aphaia Pharma, Thomson Locations: Irving , New York, U.S, GLP, Buffalo , New York, United States, Dallas, Baltimore , Maryland, Denmark, Switzerland

☆ Weight loss without Wegovy’s side-effects on biotech firms' radar
▼ + stars: | 2023-07-07 | by ( Maggie Fick | ) www.reuters.com time to read: +8 min

It leads to 22.5% weight loss, according to a Lilly trial published last year. The effect achieves far more weight loss than predecessors. An even earlier stage biotech firm, Antag Therapeutics in Denmark, told Reuters that the ballooning obesity market has improved its fundraising prospects. It curbs appetite by restoring the natural release of GLP-1 and other hormones, without causing nausea, Phase I data showed. The effect of the drug on weight loss is being tested in the Phase II study.

[1/7] Nadine, a 43-year-old tourist from the U.S., wearing a sumo wrestler costume, tries to spar against former sumo wrestler Towanoyama on the sumo ring before tourists from abroad, at Yokozuna Tonkatsu Dosukoi Tanaka in Tokyo, Japan June 30, 2023. Beneath its vaulted roof is a sumo ring and 14 tables where patrons pay 11,000 yen ($76) to eat breaded pork cutlets before watching - and joining - the action. Another former sumo wrestler, Yasuhiro Tanaka, started the restaurant after founding a company to give ex-wrestlers a second career as actors in commercials and movies. "But no, it was really, really amazing." "As sumo wrestlers, we couldn't really play around at all," said Tanaka, 47, who admitted he wasn't a particularly strong competitor.

Persons: Nadine, Towanoyama, Yokozuna Tonkatsu Dosukoi Tanaka, Issei Kato, Ohtori, Yasuhiro Tanaka, Jose Aguillar, Jumbo, Aguillar, Fumio Kishida, Tanaka, Rocky Swift, Gerry Doyle Organizations: REUTERS, Netflix, Thomson Locations: U.S, Tokyo, Japan, TOKYO, Koto, Monterrey, Mexico

Signage for Eisai Co. at the company's headquarters in Tokyo, Japan, on Friday, Feb. 3, 2023. Bloomberg | Bloomberg | Getty ImagesShares of Japanese pharmaceutical giant Eisai sank Friday after the company's Alzheimer's drug was formally approved by U.S. regulators overnight, prompting questions over investor sentiment surrounding the move. Eisai shares closed 4.67% lower after paring some of its earlier losses. Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval. "The odds for brain swelling and hemorrhage are far higher than any actual improvement," Espay, who launched a petition in June calling for the Alzheimer's treatment to not get full approval, told NBC News.

Persons: Biogen, Dr, Alberto Espay, Espay, Ivan Cheung, CNBC's, Cheung Organizations: Bloomberg, Getty, U.S, . Food, Medicare, University of Cincinnati College of, NBC News, Eisai U.S Locations: Tokyo, Japan, Eisai

☆ Stocks making the biggest moves midday: JetBlue, Affirm, Genius Sports, Sweetgreen and more
▼ + stars: | 2023-07-06 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

A JetBlue Airways Corp. plane departs at Reagan National Airport (DCA) in Arlington, Virginia, U.S., on Monday, April 6, 2020. Check out the companies making the biggest moves midday:JetBlue Airways — Shares of JetBlue Airways shed 7.18%. Sweetgreen — The salad chain jumped 15.49% following an upgrade to buy from neutral by Bank of America. Bank of America — The bank stock dropped 2.75%. Bank of America announced after the bell Wednesday it was increasing its quarterly dividend to 24 cents per share from 22 cents.

Persons: Piper Sandler, Sweetgreen, Dr Pepper —, Morgan Stanley, Genius, —, Samantha Subin, Alex Harring, Jesse Pound Organizations: JetBlue Airways Corp, Reagan National Airport, JetBlue Airways —, JetBlue Airways, American Airlines, JetBlue, Spirit Airlines, Bank of America, Ford, National Football League, Moderna, pharma, U.S Locations: Arlington , Virginia, U.S, China

☆ Marjorie Taylor Greene says she's 'sure' Instagram's new Twitter alternative will be a 'Marxist style social media experience' used to 'steal elections'
▼ + stars: | 2023-07-06 | by ( Bryan Metzger | ) www.businessinsider.com time to read: +3 min

Instagram launched "Threads" — a new alternative to Twitter — on Thursday. But the platform's already drawing criticism from the right, including Rep. Marjorie Taylor Greene. She argues that the new platform will be a "Marxist style social media experience." —Marjorie Taylor Greene 🇺🇸 (@mtgreenee) July 6, 2023The Georgia Republican added that the "Marxist style social media experience" would entail "social experimentation serving Big Pharma, the Intelligence Community, and DEI Initiatives to strengthen corporate stocks supporting garbage DEI issues and steal elections." In criticizing Threads right out of the gate, Greene is drawing on long-standing antipathies on the right towards both Meta and Zuckerberg.

Persons: Instagram, Marjorie Taylor Greene, —, Mark Zuckerberg, Donald Trump Jr, — Marjorie Taylor Greene 🇺🇸 ( Organizations: Twitter, Service

☆ DeSantis is trashing Disney all over America, accusing the company of trying to 'sexualize' children. Don't expect Disney to hit back in court, defamation experts say
▼ + stars: | 2023-07-03 | by ( Kimberly Leonard | ) www.businessinsider.com time to read: +11 min

Ron DeSantis is campaigning for president, touting his record in Florida and dragging Walt Disney World through the mud everywhere he goes. Then, DeSantis lobs an incendiary accusation: Disney, by opposing the schools bill, was promoting the "sexualization of children." Part of Disney's hurdle in the courts would be that DeSantis' statements are his own opinion. Similarly, even though DeSantis appears ready keep raising Disney at every campaign stop, a defamation lawsuit would take on another dimension that gets loads of news coverage. Even though Disney would be the plaintiff in a defamation lawsuit, materials uncovered during discovery could put Disney in the position of defending its internal communications or business practices.

Persons: DeSantis, —, Ron DeSantis, Walt, David Logan, Roy Gutterman, Newhouse, Bob Iger, Daniele Venturelli, Eugene Hoshiko, Lidsky, Barbra Streisand, Logan, Charles Glasser, Glasser, Charles Sykes, Paul Hennessy, Gutterman, John Bazemore DeSantis, that's, it's, Disney Organizations: Disney, Service, Gov, Walt Disney, Walt Disney Company, Roger Williams University School of Law, Liberty, Center, Free Speech, Syracuse University, —, University of Florida, Florida Gov, Getty, New York University, Walt Disney World, AP Locations: Florida, North Carolina, Orlando, Philadelphia, Hill, California, Smyrna, Ga

☆ Autos, health care and pharma among sectors to watch for IPOs: Freshfields
▼ + stars: | 2023-07-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAutos, health care and pharma among sectors to watch for IPOs: FreshfieldsChristoph Gleske, partner at Freshfields, discusses his outlook for capital markets in Germany as the DAX index turns 35.

Persons: Freshfields Christoph Gleske, DAX Organizations: pharma Locations: Germany

Search resuls for: "PHARMA"

25 mentions found